Please login to the form below

Not currently logged in
Email:
Password:

Invega Trinza

This page shows the latest Invega Trinza news and features for those working in and with pharma, biotech and healthcare.

J&J files three-monthly schizophrenia drug in Europe

J&J files three-monthly schizophrenia drug in Europe

The three-monthly version was approved by the FDA as Invega Trinza in May on the back of clinical data showing that the drug was effective, preventing significant return of schizophrenic ... Xeplion/Invega Sustenna is already a big earner for J&J, with

Latest news

  • FDA approves J&J’s schizophrenia drug Invega Trinza FDA approves J&J’s schizophrenia drug Invega Trinza

    The FDA has approved Johnson &Johnson's Invega Trinza (three-month paliperidone palmitate) for schizophrenia. ... Recovery looks different for everyone and the long-term symptom control offered by Invega Trinza can help patients work toward their own

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics